Case IPR 2016-01393
`Patent 7,772,209
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`WOCKHARDT BIO AG,
`Petitioner,
`
`v.
`
`ELI LILLY & COMPANY,
`Patent Owner.
`__________________
`
`Case No: IPR2016-01393
`Patent No. 7,772,209
`__________________
`
`
`
`
`
`JOINT NOTICE OF STIPULATION CONCERNING JOINDER
`
`
`Patent 7,772,209
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`WOCKHARDT BIO AG,
`Petitioner,
`
`v.
`
`ELI LILLY & COMPANY,
`Patent Owner.
`__________________
`
`Case No: IPR2016-01393
`Patent No. 7,772,209
`__________________
`
`
`
`
`
`JOINT NOTICE OF STIPULATION CONCERNING JOINDER
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`Three petitions for inter partes review have been filed seeking to join
`
`IPR2016-00318: IPR2016-01429 (filed by Apotex Inc., Apotex Corp., Emcure
`
`Pharmaceuticals Ltd., Heritage Pharma Labs Inc., Heritage Pharmaceuticals Inc.,
`
`Glenmark Pharmaceuticals Inc., USA, Glenmark Holding SA, Glenmark
`
`Pharmaceuticals Ltd., and Mylan Laboratories Ltd.); IPR2016-01340 (filed by
`
`Teva Pharmaceuticals USA, Inc. and Fresenius Kabi USA, LLC); and IPR2016-
`
`01393 (filed by Wockhardt Bio AG). The Board held an initial telephonic
`
`conference in IPR2016-00318 on July 22, 2016, in which the petitioners in
`
`IPR2016-01429 and IPR2016-01340 participated. During that conference, the
`
`Board encouraged the parties to meet and confer regarding conditions for an
`
`agreed-upon joinder. The Petitioners in IPR2016-01429, IPR2016-01340, and
`
`IPR2016-01393 (collectively, the “Joinder Petitioners”), Petitioner Sandoz, Inc.
`
`(“Sandoz” or “Lead Petitioner”), and Patent Owner Eli Lilly and Company
`
`(“Lilly”) have conferred. Sandoz has indicated that it consents to joinder by the
`
`Joinder Petitioners and has no objection to Lilly and the Joinder Petitioners’
`
`submission of this stipulation. Lilly and the Joinder Petitioners hereby stipulate
`
`and agree as follows:
`
`1.
`
`Lilly will not oppose the joinder of Joinder Petitioners to IPR2016-
`
`00318 (the “Joined Proceeding”).
`
`
`
`2
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`Lilly waives its right to file a Patent Owner Preliminary Response in
`
`2.
`
`IPR2016-01429, IPR2016-01340, and IPR2016-01393.
`
`3.
`
`So long as Lead Petitioner is not terminated as a party, Lead Petitioner
`
`will retain control over petitioners’ side of the Joined Proceeding, will conduct all
`
`argument and examination of witnesses for that side, and will submit all
`
`substantive written submissions for that side. Joinder Petitioners will act as silent
`
`understudies in the proceedings, and thus will not (1) file any papers or exhibits in
`
`the Joined Proceeding, except for pro hac vice motions, updated mandatory
`
`notices, and similar administrative filings that do not constitute argument or
`
`evidence relating to the merits; (2) serve objections or discovery requests in
`
`connection with the Joined Proceeding; however, these restrictions do not apply to
`
`any discovery requests Lilly may serve on a Joinder Petitioner; (3) participate in
`
`the questioning of any witness or the defense of any witness deposition in the
`
`Joined Proceeding; (4) participate in a speaking role in any telephonic conference
`
`before the Board in the Joined Proceeding; or (5) participate in oral argument in
`
`the Joined Proceeding. Joinder Petitioners may, however, attend all depositions,
`
`telephonic conferences, and oral argument in the Joined Proceeding, and will be
`
`served with all papers and exhibits served by Lead Petitioner on Patent Owner or
`
`by Patent Owner on Lead Petitioner. Notwithstanding the above, Joinder
`
`Petitioners may speak or otherwise respond if there is an argument, question, or
`
`
`
`3
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`inquiry directed specifically to one or more Joinder Petitioners, or that is about one
`
`or more Joinder Petitioners specifically or the position of one or more Joinder
`
`Petitioners specifically.
`
`4.
`
`The parties agree that the arguments and evidence presented in
`
`Joinder Petitioners’ petitions is duplicative of the arguments and evidence
`
`presented in Lead Petitioner’s petition. The Joined Petitioners agree to proceed in
`
`the instant IPR based only upon the arguments and evidence advanced by Lead
`
`Petitioner.
`
`5.
`
`The presence of Joinder Petitioners in the Joined Proceeding shall not
`
`be a basis for any alteration of the schedule, nor shall Joinder Petitioners be
`
`allocated time or otherwise affect the times allocated for cross-examination,
`
`redirect, or re-cross examination of any witness.
`
`6.
`
`In the event that Lead Petitioner is terminated from the Joined
`
`Proceeding by settlement or for any other reason, the remaining parties agree to
`
`confer in good faith regarding a fair and efficient framework for completing the
`
`remainder of the Joined Proceeding, including whether the submission of
`
`additional expert declarations from Joinder Petitioners (such as in the event that
`
`Lead Petitioner’s expert is unavailable to the Joinder Petitioners) is necessary.
`
`
`Date: August 22, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`/Dov P. Grossman/
`
`
`
`
`Dov P. Grossman
`Reg. No. 72,525
`
`Lead Counsel for
`
`Eli Lilly and Company
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, D.C. 20005
`202-434-5812 (Telephone)
`202-434-5029 (Facsimile)
`dgrossman@wc.com
`
`
`
`
`
`
`
`/Deanne M. Mazzochi (with permission)/
`Deanne M. Mazzochi
`
`
`
`Reg. No. 50,158
`
`
`
`
`Lead Counsel for
`
`
`
`Apotex Inc. and Apotex Corp.
`
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard St., Ste. 500
`
`
`Chicago, IL 60654
`
`
`
`312-527-2157 (Telephone)
`
`
`312-527-4205 (Facsimile)
`
`
`dmazzochi@rmmslegal.com
`
`
`
`
`
`
`
`
`
`
`/Patrick A. Doody (with permission)/
`Patrick A. Doody
`
`
`
`Reg. No. 35,022
`
`
`
`
`Lead Counsel for
`
`
`
`
`Wockhardt Bio AG
`
`Case IPR 2016-01393
`Patent 7,772,209
`/Gerard A. Haddad (with permission)/
`
`Gerard A. Haddad
`Reg. No. 41,811
`Counsel for Glenmark
`Pharmaceuticals Inc., USA, Glenmark
`Holding SA, and Glenmark
`Pharmaceuticals Ltd.
`
`Blank Rome LLP
`The Chrysler Building
`405 Lexington Ave.
`New York, NY 10174
`212-885-5135 (Telephone)
`917-591-6921 (Facsimile)
`GHaddad@BlankRome.com
`
`/Gary J. Speier (with permission)/
`Gary J. Speier
`
`
`
`Reg. No. 45,458
`Lead Counsel for
`Teva Pharmaceuticals USA, Inc.
`
`Carlson, Caspers, Vandenburgh,
`Lindquist, & Schuman
`225 South Sixth St., Ste. 4200
`Minneapolis, MN 55402
`612-436-9600 (Telephone)
`612-436-9605
`gspeier@carlsoncaspers.com
`
`/Paul M. Zagar (with permission)/
`Paul M. Zagar
`Reg. No. 52,392
`Counsel for Emcure Pharmaceuticals
`Ltd., Heritage Pharma Labs Inc., and
`Heritage Pharmaceuticals Inc.
`
`
`Pillsbury Winthrop Shaw Pittman LLP
`1650 Tysons Blvd.
`
`
`
`
`
`
`Blank Rome LLP
`The Chrysler Building
`
`5
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`405 Lexington Ave.
`New York, NY 10174
`212-885-5290 (Telephone)
`917-332-3063 (Facsimile)
`PZagar@BlankRome.com
`
`/Cynthia L. Hardman (with
`permission)/
`
`Cynthia L. Hardman
`Reg. No. 53,179
`Counsel for Fresenius Kabi USA,
`LLC
`
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`212-813-8800 (Telephone)
`212-355-3333 (Facsimile)
`chardman@goodwinprocter.com
`
`
`
`
`
`
`McLean, VA 22102
`
`703-770-7755 (Telephone)
`
`703-770-7901 (Facsimile)
`patrick.doody@pillsburylaw.com
`
`
`
`
`
`
`
`
`
`/Thomas J. Parker (with permission)/
`
`
`
`Thomas J. Parker
`
`
`Reg. No. 42,062
`
`Counsel for Mylan Laboratories Ltd.
`
`
`
`Alston & Bird LLP
`90 Park Ave., 15th Floor
`New York, NY 10016
`
`212-210-9529 (Telephone)
`212-210-9444 (Facsimile)
`thomas.parker@alston.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing Joint Notice of
`
`
`
`Stipulation Concerning Joinder was served on August 22, 2016 by delivering a
`
`copy via electronic mail on the following attorneys of record:
`
`Ralph J. Gabric
`Reg. No. 34,167
`rgabric@brinksgilson.com
`
`Brinks Gilson & Lione
`455 Cityfront Plaza Drive
`Suite 3600 NBC Tower
`Chicago, IL 60611-5599
`T: 312-321-4200; F: 312-321-4299
`
`Bryan T. Richardson, Ph.D.
`Reg. No. 70,572
`brichardson@brinksgilson.com
`
`Brinks Gilson & Lione
`4721 Emperor Blvd.
`Suite 220
`Durham, NC 27703-8580
`T: 919-998-5700; F: 919-998-5701
`
`Counsel for Sandoz Inc.
`
`John D. Polivick
`Reg. No. 57,926
`jpolivick@rmmslegal.com
`
`William A. Rakoczy
`Pro hac vice to be filed
`wrakoczy@rmmslegal.com
`
`Rakoczy Molino Mazzochi Siwik LLP
`
`
`
`
`
`Laura Lydigsen
`Pro hac vice
`llydigsen@brinksgilson.com
`
`
`
`
`
`
`
`
`Deanne M. Mazzochi
`Reg. No. 50,158
`dmazzochi@rmmslegal.com
`
`Patrick C. Kilgore
`Reg. No. 69,131
`pkilgore@rmmslegal.com
`
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`
`6 West Hubbard Street, Suite 500
`Chicago, IL
`P: 312-527-2157/F: 312-527-4205
`
`Attorneys for Apotex Inc. and Apotex
`Corp.
`
`Thomas J. Parker
`Reg. No. 42,062
`thomas.parker@alston.com
`
`Alston & Bird LLP
`90 Park Avenue, 15th Floor
`New York, NY 10016
`P: 212-210-9529/F: 212-210-9444
`
`Counsel for Mylan Laboratories Limited
`
`Gerard A. Haddad
`Reg. No. 41,811
`GHaddad@BlankRome.com
`
`Blank Rome LLP
`The Chrysler Building
`405 Lexington Ave.
`New York, NY 10174
`P: 212-885-5135/F: 917-591-6921
`
`Counsel for Glenmark Pharmaceuticals
`Inc., USA, Glenmark Holding SA, and
`Glenmark Pharmaceuticals Ltd.
`
`Paul M. Zagar
`Reg. No. 52,392
`PZagar@BlankRome.com
`
`Blank Rome LLP
`The Chrysler Building
`405 Lexington Ave.
`New York, NY 10174
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`
`
`Mark D. Schuman
`Reg. No. 31,197
`mschuman@carlsoncaspers.com
`
`
`
`
`
`
`
`Bryan P. Collins
`Reg. No. 43,560
`P: 703-770-7538
`bryan.collins@pillsburylaw.com
`
`
`P: 212-885-5290/F: 917-332-3063
`
`Counsel for Emcure Pharmaceuticals
`Ltd., Heritage Pharma Labs Inc., and
`Heritage Pharmaceuticals Inc.
`
`Gary J. Speier
`Reg. No. 45,458
`gspeier@carlsoncaspers.com
`
`Carlson, Caspers, Vandenburgh,
`Lindquist & Schuman
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`P: 612-436-9600
`F: 612-436-9605
`
`Cynthia Lambert Hardman
`Reg. No. 53,179
`chardman@goodwinprocter.com
`
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`P: 212-813-8800
`F: 212-355-3333
`
`Attorneys for Teva Pharmaceuticals
`USA, Inc. and Kabi Fresenius USA,
`LLC
`
`Patrick A. Doody
`Reg. No. 35,022
`P: 703-770-7755
`patrick.doody@pillsburylaw.com
`
`Pillsbury Winthrop Shaw Pittman LLP
`1650 Tysons Boulevard
`McLean, VA 22102
`
`
`
`
`
`
`
`Case IPR 2016-01393
`Patent 7,772,209
`
`
`
`/Dov P. Grossman/
`Dov P. Grossman
`Reg. No. 72,525
`Lead Counsel for Patent Owner
`
`
`F: 312-527-4205
`
`Attorneys for Wockhardt Bio AG
`
`
`
`
`
`
`
`
`
`
`
`
`Date: August 22, 2016
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
